Hirudin variants production by genetic engineered microbial factory
Research article published in Biotechnology & genetic engineering reviews (2018)
Abstract
Hirudin was discovered as an active anticoagulant in leech extracts almost 60 years ago. Since their initial discovery, hirudin and its variants have been produced with various anti-thrombotic, cancer cell inhibition, diabetic cataract treatment and anti-fatigue activities. Some hirudin variants have been approved for clinical use and released into the marketplace. Recent progress has seen made in relation to hirudin variants expressed in several well-established microbial hosts, including Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris and others, with high levels of activity and yield. This review summarizes the current progress on hirudin production using microbial producers, and considers the outlook for future development.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Резюме
Hirudin was discovered as an active anticoagulant in leech extracts almost 60 years ago. Since their initial discovery, hirudin and its variants have been produced with various anti-thrombotic, cancer cell inhibition, diabetic cataract treatment and anti-fatigue activities.
Почему это важно для гирудотерапии
Relevant to the development and clinical application of leech-derived pharmaceutical compounds.
Цитирование
Hirudin variants production by genetic engineered microbial factory.
Zhang J, Lan N · Biotechnology & genetic engineering reviews, 2018
Связанный клинический контекст
Узнайте, как это исследование связано с клинической практикой
Добавлено в библиотеку ASH: March 18, 2026 · Последнее обновление сайта: March 18, 2026